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Abstract: Elevated intraocular pressure (IOP) is a signiﬁ cant risk factor for the development and 
progression of glaucomatous optic neuropathy, but increasingly we appreciate that non-pressure 
dependent factors, are key to our understanding of the pathophysiology of these neurodegenerative 
diseases, that target the retinal ganglion cell. As we try to expand therapy beyond IOP control, 
medications are being assessed for their neuroprotective abilities. Brimonidine is an effective 
ocular hypotensive treatment both as a ﬁ rst and second line agent, in the management of glaucoma 
and ocular hypertension. Brimonidine tartrate 0.2% is generally safe and well tolerated, with 
its safety proﬁ le further enhanced in the altered formulation brimonidine-Purite™ 0.1%. Beyond 
brimonidine’s pressure lowering capacity, laboratory and early clinical evidence supports its 
neuroprotective potential. We await validation of this in human clinical trials.
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Introduction
Glaucomatous optic neuropathy (GON) is the manifestation of a group of diseases 
that progressively destroy retinal ganglion cells and if undetected or untreated, cause 
visual ﬁ eld loss and functional disability. With increasing prevalence in an ageing 
population,1,2 identiﬁ cation and treatment of patients to prevent visual disability have 
signiﬁ cant implications for our communities.
As elevated intraocular pressure (IOP) is the most signiﬁ cant risk factor for develop-
ing glaucomatous optic neuropathy, and for its progression, its reduction and control 
have been the mainstays of glaucoma management. However non-pressure-dependent 
factors also contribute to the pathophysiology of glaucoma. Glaucomatous damage 
develops in many individuals despite the existence of IOP readings consistently in 
the usual range (less than 21 mmHg),2,3 conversely in individual patients, despite 
IOP-reduction, there is continued progression of the GON.4
With increased recognition of the neurodegenerative nature of glaucoma, 
antiglaucoma medications are being assessed for their ability to exert clinical beneﬁ ts 
beyond IOP control, speciﬁ cally their ability to protect retinal ganglion cells and to 
prevent neuronal cell death (neuroprotection).5
Brimonidine tartrate 0.2% ophthalmic solution (Alphagan®, Allergan) is a highly 
selective alpha-2 adrenergic agonist, which lowers IOP through increased uveoscleral 
outﬂ ow and decreased aqueous humour production.6 Beyond this there has been 
interest in whether brimonidine has neuroprotective effects both in the laboratory and 
in clinical trials.
Pharmacology and mechanism of action of brimonidine
Brimonidine tartrate, a third generation alpha-2 adrenergic agonist, has more than 
1000-fold selectivity for alpha-2 over alpha-1 receptors.7 This gives it a distinct 
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advantage over the ﬁ rst and second generation clonidine and 
apraclonidine by reducing the risk of systemic side effects, 
such as systemic hypotension, bradycardia and sedation, as 
well as reducing the alpha-1 mediated ocular side effects seen 
more commonly with apraclonidine: conjunctival blanching, 
mydriasis and eyelid retraction.7
On topical application, brimonidine readily penetrates the 
cornea and results in a reduction of the IOP within 1 hour. 
Peak effect is achieved within 2 to 3 hours and the trough 
drug effect occurs approximately 10 to 14 hours after instil-
lation.8 In most parts of the world, brimonidine is dosed twice 
daily and its rapid metabolism and short half-life help to 
reduce potential cardiovascular and respiratory side effects.7 
Brimonidine appears to lower IOP by a dual mechanism of 
action. Initial dosing causes a reduction in aqueous humour 
production whereas with chronic dosing, the predominant 
effect is an increase in uveoscleral outﬂ ow.8
Evidence for neuroprotection
Neuroprotection in glaucoma refers to the ability to preserve 
anatomic and functional integrity of the retinal ganglion 
cells other than by reduction of IOP, thus preserving the 
visual ﬁ eld.9
To evaluate the potential of a pharmacological agent to be 
useful clinically as a neuroprotectant in glaucoma, 4 criteria 
have been proposed.10
1. There must be speciﬁ c target receptors in the retina or 
optic nerve.
2.  There must be laboratory evidence that supports it has a 
mechanism of action that enhances a neuron’s resistance 
to injury.
3.  It must be available at the retina or optic nerve at phar-
macological concentrations required for a neuroprotective 
effect after topical dosing, and
4.  It must have demonstrated neuroprotective activity in 
prospective randomized clinical trials.
We will review current evidence that assesses brimonidine 
with respect to these criteria.
Laboratory evidence has demonstrated alpha-2 receptors 
in the retina. Immunohistochemical studies have shown the 
existence of alpha adrenergic receptors in human, bovine and 
porcine retina11, and in particular in the ganglion cell layer 
and inner nuclear layer of the rat retina.10
Brimonidine requires a concentration of 2 nM to activate 
alpha-2 adrenergic receptors signiﬁ cantly.12 In a clinical study 
of 17 patients scheduled to undergo pars plana vitrectomy, 
topical brimonidine 0.2% was administered twice daily 
for 5 to 14 days prior to surgery. At the time of surgery 
an undiluted core of vitreous humour was obtained and 
brimonidine concentrations, determined. The cohort included 
phakic, aphakic and pseudo-phakic patients. The mean 
brimonidine concentration measured in the vitreous was 
185 nM. As this is well above the 2 nM required for receptor 
activation,13 it seems reasonable to assume that retinal levels 
are likely to be sufﬁ cient to activate the alpha 2 receptors 
following topical instillation. Phakic eyes demonstrated a 
lower concentration than did pseudophakic or aphakic eyes, 
with phakic eyes achieving a mean concentration of 9.3 nM 
of brimonidine, as compared with 164 nM in aphakic eyes 
and 256 nM in pseudophakic eyes.
Studies of the effect of brimonidine on experimental 
animal models of optic nerve injury provide further evidence 
of its neuroprotective potential. In pre-clinical studies using 
the chronic ocular hypertensive rat model, the effect of retinal 
ganglion cell survival was assessed following subcutaneous 
administration of brimonidine, compared with timolol as the 
control. In brimonidine-treated eyes, retinal ganglion cell 
(RGC) death was reduced up to 50%, whereas with timolol, 
no neuroprotective effect was demonstrated.14 Although 
both drugs have comparable IOP lowering efﬁ cacy, neither 
drug lowered the IOP significantly when administered 
systemically, suggesting that the beneﬁ cial effect seen, 
directly related to the neuroprotective effect. Further 
analysis of a rat model of glaucoma, where brimonidine 
was administered intraperitoneally, revealed attenuation of 
ganglion cell death independent of IOP reduction.15
Retinal injury and brimonidine effects on this have been 
assessed with two rat models: induction of retinal ischemia 
and then reperfusion, as well as crush injury to the optic 
nerve. Administration of brimonidine enhanced retinal 
ganglion cell survival in both models.16 In a similar rat model 
of retinal ischemia, Donello et al demonstrated preservation 
of the ERG b wave.17
While the mechanism by which this neuroprotection is 
mediated is not completely understood, alpha-2 adrenergic 
receptor stimulation might inhibit signals that trigger the 
apoptotic cascade in the RGC.18
Brimonidine appears to meet the ﬁ rst 3 criteria required 
of a neuroprotectant; support of clinical trials is necessary 
to meet the fourth.
An initial randomized controlled study, comparing 
the effects of brimonidine and timolol on visual field 
loss, after acute primary angle closure crisis, found no 
difference in prevalence of visual field defects or rate of 
field progression between the brimonidine and timolol 
treated groups.19
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Another randomized double-masked pilot study evaluated 
the neuroprotective efﬁ cacy of brimonidine, when applied to 
eyes of patients undergoing laser treatment for extrafoveal and 
juxtafoveal choroidal neovascularization.20 Twenty eyes were 
randomized to receive brimonidine 0.2% (study group, 11 eyes) 
or placebo (matched control group, 9 eyes). Brimonidine was 
instilled twice daily for 4 to 48 hours pre-laser treatment and 
was continued for one month post- laser. In each group, 2 eyes 
had severe visual loss from recurrence of the CNV but in the 
remainder, signiﬁ cant improvement of visual acuity was noted 
in the study group but not in the control group. The authors 
proposed that brimonidine improved the visual outcome 
of laser treated CNV by protecting the neuroretina against 
laser-induced collateral damage.
More recently Tsai et al in a prospective unmasked 
study compared the effects of brimonidine 0.2% with 
timolol 0.5% on retinal nerve ﬁ ber layer (RNFL) thick-
ness in ocular hypertensive patients. Using scanning laser 
polarimetry (GDx) to measure the RNFL, they demonstrated 
quantitatively less progression of RNFL damage with 
brimonidine versus timolol 0.5% in these patients over 
12 months.21
In a prospective clinical trial, Gandolﬁ  et al compared 
visual ﬁ eld deterioration rates in patients randomized to either 
topical brimonidine or to 360° argon laser trabeculoplasty 
(ALT). After 18 months of follow up, despite brimonidine 
reducing IOP less than the ALT, it appeared to be more 
effective than the laser in reducing ﬁ eld deterioration, in 
progressing glaucomatous eyes.22
Contrast sensitivity has also been shown to improve 
in brimonidine treated eyes of newly diagnosed glaucoma 
patients. This effect was independent of IOP lowering effects, 
supporting a neuroprotective mechanism.23
The Low-Pressure Glaucoma Treatment Study (LoGTS) 
is a large double-masked multi-center, randomized clini-
cal trial comparing the visual outcomes of “low pressure 
glaucoma” patients randomized to receive either twice daily 
brimonidine tartrate 0.2% or timolol maleate 0.5%. One 
hundred and ninety patients were recruited between 1998 
and 2000 and have been followed for at least 4 years. The 
main study outcome is visual ﬁ eld stability.24,25 Results are 
expected shortly; they are hoped to advance understanding 
of these patients, where non-pressure dependent factors are 
more likely to be operative.25
Clinical effi cacy studies
Since its introduction in the Australasian market in October 
1997, there has been strong growth in the use of brimonidine 
tartrate 0.2% both as a ﬁ rst and second line treatment in 
patients with POAG and ocular hypertension.26
The hypotensive efﬁ cacy of brimonidine as monotherapy 
in glaucoma and ocular hypertension has been studied in a 
many clinical trials and compared with all other classes of 
topical hypotensive agents.
Initial clinical trials assessed efﬁ cacy of brimonidine 
tartrate 0.2% compared with timolol maleate 0.5%. One 
year data in 2 clinical trials found that brimonidine produced 
similar mean decreases in the IOP at peak compared with 
timolol, but at trough, the hypotensive effect was less than 
with timolol. Overall brimonidine demonstrated sustained 
IOP lowering efﬁ cacy comparable with timolol.27,28,29 When 
followed for 3 or 4 years of continuous use, brimonidine 
maintained an IOP lowering efﬁ cacy comparable with timolol 
and assessment of long term visual ﬁ eld preservation in both 
groups, was essentially the same.30,31
Brimonidine has also been compared with betaxolol 
0.25%, which because of its relative cardio-selective adren-
ergic antagonist activity, offers greater safety from pulmo-
nary side effects, than the non-selective beta-blockers, such 
as timolol and because of its pharmacokinetics, is also less 
likely to precipitate cardiac side effects.32‚33
Judging clinical success after 4 months (IOP reduction, 
quality of life effects and adverse effects), brimonidine 0.2% 
showed a greater clinical success than betaxolol.34 A previous 
clinical trial reported similar results.35
A meta-analysis of 3 clinical studies comparing, the efﬁ cacy 
and harm of latanoprost for IOP reduction in glaucoma patients, 
with brimonidine, found that there was no signiﬁ cant reduction 
in the mean IOP at 3 months post treatment in the latanoprost 
group compared with the brimonidine group. Pooled data of 
adverse events between these two drugs found that patients in 
the brimonidine group had a signiﬁ cant increase in the number 
of ocular adverse events (excluding hyperemia).36
Three separate studies evaluated the efﬁ cacy and safety 
of brimonidine compared with dorzolamide when used as 
monotherapy. While there was no overall difference in IOP-
lowering efﬁ cacy, ocular stinging and burning were more 
common with dorzolamide.37,38,39
Several randomized controlled studies have assessed 
efﬁ cacy and safety of brimonidine as adjunctive therapy. 
When added to ongoing beta-blocker therapy, brimonidine 
was shown to reduce IOP signiﬁ cantly.40,41 Similarly, when 
added to latanoprost, brimonidine demonstrated signiﬁ cant 
additional IOP lowering capacity.41,42
Clinical trials assessing the efﬁ cacy of a ﬁ xed combination 
of brimonidine 0.2% and timolol 0.5% (contribution of 
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elements studies) showed mean IOP reductions were greater 
with the ﬁ xed combination (Combigan®, Allergan) than when 
the individual agents each were used alone.43 The advantage 
of the ﬁ xed combination, ease and convenience of instillation, 
without drug dilution seen when 2 drops are instilled too close 
together in time, might result in better patient compliance, 
thus leading to the higher success rate with this treatment.44
These efﬁ cacy studies support the versatility of brimo-
nidine as an effective ocular hypotensive agent in patients 
with glaucoma and ocular hypertension. It is effective as 
monotherapy and as an adjunctive agent, with the effect 
being maintained over time.
Safety and tolerability
Evaluating efﬁ cacy and safety of brimonidine 0.2% after 1, 3 
and 4 years of use, various studies have supported its overall 
safety and tolerability: no clinically signiﬁ cant effects on 
mean heart rate, blood pressure or pulmonary function.28,29,30 
Unlike timolol, which can induce cardiovascular and pulmo-
nary side effects,45 brimonidine generally is not contraindi-
cated in patients with cardiopulmonary disease.
These studies supported a favorable safety proﬁ le for 
brimonidine. The most common systemic side effects 
included dry mouth, fatigue or drowsiness and headache.28,29,30 
and the most common ocular side effects seen included ocular 
irritation, follicular conjunctivitis and blurred vision.
After 1 and 4 years of use, comparative studies between 
timolol and brimonidine showed equivalent tolerability. 
There was a slightly greater frequency of burning and 
stinging from timolol, and of oral dryness and ocular allergies 
in the brimonidine group.30 When brimonidine was compared 
with betaxolol suspension, both agents were equally well 
tolerated,32,35 although a higher degree of hyperemia has been 
reported with betaxolol in another clinical trial.46
Brimonidine is more stable and less likely to produce an 
allergic reaction compared with apraclonidine.47 However, 
the major obstacle to long-term use of brimonidine is its 
propensity to cause ocular allergic reactions,27,28 with reported 
incidence rates of follicular conjunctivitis of 12.7% (twice 
daily dosing) and 15.7% (thrice daily dosing) at 1 year.27 
For the third year of use, this rate was 4.2%.48 In all cases of 
allergy, symptoms resolved following discontinuation.
Demographic and clinical factors associated with 
brimonidine-induced allergy showed that affected individuals 
had a higher frequency of ocular allergy to all eye drops and 
a reduction of tear ﬁ lm production.49
Allergan Inc., (Irvine, CA) released a reformulated 
solution of brimonidine, preserved with chlorine dioxide 
(Purite™) rather than benzalkonium chloride (BAK), and 
reduced the concentration of brimonidine to 0.15%. BAK, 
the most common antimicrobial preservative used in topical 
ophthalmic preparations, has the potential to accumulate in 
ocular tissues, and to cause toxicity and/or adverse effects, 
particularly if there is chronic dosing with multiple glau-
coma therapies.50,51 In contrast Purite (which is converted 
to natural tear components when exposed to sunlight) has a 
wide spectrum of antimicrobial activity and a very low level 
of toxicity. This formulation (brimonidine 0.15%–Purite), 
despite having 25% less active drug than brimonidine 0.2%, 
has comparable hypotensive efﬁ cacy, as well as having 41% 
lower incidence of allergic conjunctivitis.52,53 Currently this 
formulation is only available through the special access 
scheme for patients in Australia.
Brimonidine is absolutely contra-indicated in children; 
because of a less mature blood:brain barrier, they are 
susceptible to potentially serious central nervous system side 
effects including sleepiness, lethargy, bradycardia, hypoten-
sion, apnea and coma.54
Patient perspectives, acceptability, 
satisfaction, implications
of neuroprotection
Effectiveness of any medication in the treatment of glau-
coma depends on patient adherence to and persistence with 
the therapeutic regimen. Factors that inﬂ uence these patient 
factors include, absence of symptoms from their disease, 
the number of topical medications, dosing frequency and 
adverse effects associated with instillation, such as burning 
and stinging.55,56 Quality of life assessments, as scored on 
the Glaucoma Disability Index, of patients on brimonidine 
as monotherapy, showed no worsening in the quality of life 
during the study period.34
Fixed combinations of brimonidine 0.2%/timolol 0.5% 
(Combigan®) have demonstrated signiﬁ cantly lower rates 
of allergy of up to 50%, when compared with the individual 
components43,57 and greater tolerability, with less burning, 
when compared with dorzolamide/timolol combinations.58 
This beneﬁ t may be attributable to the lower concentration 
of BAK that is present in Combigan® compared with the 
individual components and with the ﬁ xed combination of 
dorzolamide/timolol.43 It has also been suggested that the 
topical beta blocker effects of timolol, may have a protec-
tive effect in reducing ocular allergy.59,60 Its vasoconstric-
tive effect and reduced conjunctival hyperemia may be the 
mechanism by which Combigan® achieves better tolerance 
and reduced local side effects when applied to the eye.43
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When comparing quality of life measures and patient 
satisfaction between dosing with brimonidine 2% and 
brimonidine–Purite™ 0.15%, patients reported supe-
rior satisfaction and comfort ratings with the latter 
formulation.52
Overall brimonidine 0.2% demonstrates hypotensive 
efﬁ cacy, and is tolerated by the majority of patients. Future 
availability of the Purite™ formulation will reduce the 
frequency of topical allergy, without compromising IOP 
lowering efﬁ cacy. Its twice daily dosing, availability in ﬁ xed 
dose combinations, together with its adult safety proﬁ le 
contributes to satisfaction, compliance and persistence with 
treatment If clinical evidence supports neuroprotective 
beneﬁ ts, brimonidine might offer a new therapeutic paradigm, 
to preserve visual function, beyond IOP reduction.
Conclusions, place in therapy
Brimonidine tartrate 0.2%, a highly selective alpha-2 
adrenergic agonist, is generally an effective and safe ocular 
hypotensive agent for the long term management of glaucoma 
and ocular hypertension, whether used as monotherapy, 
adjunctive therapy or replacement therapy in the treatment 
of glaucoma. Limiting the success of brimonidine 2% as a 
ﬁ rst line agent, is its rate of topical allergy, but this is less 
common with the brimonidine–Purite™ formulation.
If clinical studies with brimonidine support laboratory 
evidence of a neuroprotective effect, our treatment paradigm 
will shift beyond IOP-reduction, and begin to focus on our 
ability to preserve visual function for patients, through both 
neuroprotection and ocular hypotension.
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